Cell and GeneTherapy group, King’s College London, The Rayne Institute, 123Cold harbour Lane, London [No. SE59NU]

Link to this page

http://vinar.vin.bg.ac.rs/APP/faces/project.xhtml?project_id=Cell+and+GeneTherapy+group%2C+King%E2%80%99s+College+London%2C+The+Rayne+Institute%2C+123Cold+harbour+Lane%2C+London+%5BNo.+SE59NU%5D&item_offset=0&author_offset=0&sort_by=dc.date.issued

Cell and GeneTherapy group, King’s College London, The Rayne Institute, 123Cold harbour Lane, London [No. SE59NU]

Authors

Publications

VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma

Todorović, Lidija; Stanojević, Boban

(2023) 

TY  - JOUR
AU  - Todorović, Lidija
AU  - Stanojević, Boban
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10607
AB  - Papillary thyroid carcinoma (PTC) is the most common type of endocrine cancer, with an increasing incidence worldwide. The treatment of PTC is currently the subject of clinical controversy, making it critically important to identify molecular markers that would help improve the risk stratification of PTC patients and optimize the therapeutic approach. The Von Hippel–Lindau (VHL) tumor suppressor gene has been implicated in tumorigenesis of various types of carcinoma and linked with their aggressive biological behavior. The role of VHL in the origin and development of PTC have only recently begun to be revealed. In this narrative review, we attempt to summarize the existing knowledge that implicates VHL in PTC pathogenesis and to outline its potential significance as a candidate molecular biomarker for the grouping of PTC patients into high and low risk groups. © 2022 Todorović and Stanojević.
T2  - Bosnian Journal of Basic Medical Sciences
T1  - VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma
VL  - 23
IS  - 1
SP  - 26
EP  - 36
DO  - 10.17305/bjbms.2022.7850
ER  - 
@article{
author = "Todorović, Lidija and Stanojević, Boban",
year = "2023",
abstract = "Papillary thyroid carcinoma (PTC) is the most common type of endocrine cancer, with an increasing incidence worldwide. The treatment of PTC is currently the subject of clinical controversy, making it critically important to identify molecular markers that would help improve the risk stratification of PTC patients and optimize the therapeutic approach. The Von Hippel–Lindau (VHL) tumor suppressor gene has been implicated in tumorigenesis of various types of carcinoma and linked with their aggressive biological behavior. The role of VHL in the origin and development of PTC have only recently begun to be revealed. In this narrative review, we attempt to summarize the existing knowledge that implicates VHL in PTC pathogenesis and to outline its potential significance as a candidate molecular biomarker for the grouping of PTC patients into high and low risk groups. © 2022 Todorović and Stanojević.",
journal = "Bosnian Journal of Basic Medical Sciences",
title = "VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma",
volume = "23",
number = "1",
pages = "26-36",
doi = "10.17305/bjbms.2022.7850"
}
Todorović, L.,& Stanojević, B.. (2023). VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma. in Bosnian Journal of Basic Medical Sciences, 23(1), 26-36.
https://doi.org/10.17305/bjbms.2022.7850
Todorović L, Stanojević B. VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma. in Bosnian Journal of Basic Medical Sciences. 2023;23(1):26-36.
doi:10.17305/bjbms.2022.7850 .
Todorović, Lidija, Stanojević, Boban, "VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma" in Bosnian Journal of Basic Medical Sciences, 23, no. 1 (2023):26-36,
https://doi.org/10.17305/bjbms.2022.7850 . .
2
2